Weekly Vaccination with Copaxone as a Potential Therapy for Dry Age Related Macular Degeneration
Closed to Enrollment
The purpose of this study is to evaluate how tolerable, safe, and effective it is to give Copaxone subcutaneous injections to adults with dry age related macular degeneration (Dry AMD).
Ages Eligible for Study: 50 years old and older
Genders Eligible for Study: Both
Subjects with the diagnosis of dry age related macular degeneration
Aged 50 to 75 years.
Must have the presence of drusen and no geographic atrophy